Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Tata Chemicals surges on Tata Sons listing buzz
Tata Chemicals shares surged on Thursday, driven by the RBI’s new guidelines for upper-layer NBFCs, sparking hopes for a Tata Sons listing. Analysts suggest this